<![CDATA[Choosing Between Approved Frontline Metastatic Pancreatic Cancer Regimens]]>

Summary

Experts discussed comparative efficacy of NALIRIFOX, FOLFIRINOX, and gemcitabine/nab-paclitaxel as frontline treatment options for metastatic pancreatic cancer. This is a routine expert discussion article without new clinical data or regulatory developments.